We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The mean of analysts' price targets for First American Financial (FAF) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 27.3% in Hawkins (HWKN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Extreme Networks (EXTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The consensus price target hints at a 32.8% upside potential for FTAI Aviation (FTAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in SM Energy (SM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The consensus price target hints at a 46.2% upside potential for Nvidia (NVDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View the Zacks #1 Rank List
Zacks.com Most Recent Articles
Robust Trading, IB Fee Growth to Support Morgan Stanley's Q1 Earnings
Analyst Blog
by Zacks Equity Research
MS to report Q1 earnings on April 15. Wall Street expects $19.62B revenues, EPS $3.08, with advisory fees +52% on trading and IB strength.
GSNegative Net Change JPMPositive Net Change MSPositive Net Change
banking earnings finance
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
Tale of the Tape
by Zacks Equity Research
electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ECORPositive Net Change FDMTNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Wall Street Analysts Think First American Financial (FAF) Could Surge 28.15%: Read This Before Placing a Bet
Tale of the Tape
by Zacks Equity Research
The mean of analysts' price targets for First American Financial (FAF) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
FAFPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Hawkins (HWKN)? Wall Street Analysts Think 27.26%
Tale of the Tape
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.3% in Hawkins (HWKN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HWKNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Extreme Networks (EXTR) Have the Potential to Rally 32.39% as Wall Street Analysts Expect?
Tale of the Tape
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Extreme Networks (EXTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
EXTRPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%
Tale of the Tape
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DMRAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 32.81% Upside in FTAI Aviation (FTAI): Can the Stock Really Move This High?
Tale of the Tape
by Zacks Equity Research
The consensus price target hints at a 32.8% upside potential for FTAI Aviation (FTAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FTAINegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does SM Energy (SM) Have the Potential to Rally 27.89% as Wall Street Analysts Expect?
Tale of the Tape
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in SM Energy (SM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SMNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 46.16% Upside in Nvidia (NVDA): Can the Stock Really Move This High?
Tale of the Tape
by Zacks Equity Research
The consensus price target hints at a 46.2% upside potential for Nvidia (NVDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NVDAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?
Tale of the Tape
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NRIXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate